BRPI0913119A2 - Inibidores de sinalização de proteína wnt - Google Patents
Inibidores de sinalização de proteína wntInfo
- Publication number
- BRPI0913119A2 BRPI0913119A2 BRPI0913119-1A BRPI0913119A BRPI0913119A2 BR PI0913119 A2 BRPI0913119 A2 BR PI0913119A2 BR PI0913119 A BRPI0913119 A BR PI0913119A BR PI0913119 A2 BRPI0913119 A2 BR PI0913119A2
- Authority
- BR
- Brazil
- Prior art keywords
- signaling inhibitors
- protein signaling
- wnt protein
- wnt
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13014908P | 2008-05-27 | 2008-05-27 | |
| US20427909P | 2009-01-02 | 2009-01-02 | |
| PCT/US2009/045340 WO2009155001A2 (en) | 2008-05-27 | 2009-05-27 | Wnt protein signalling inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0913119A2 true BRPI0913119A2 (pt) | 2015-07-28 |
Family
ID=41050590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0913119-1A BRPI0913119A2 (pt) | 2008-05-27 | 2009-05-27 | Inibidores de sinalização de proteína wnt |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8445491B2 (pt) |
| EP (1) | EP2303862B1 (pt) |
| JP (1) | JP2011521958A (pt) |
| KR (1) | KR20110014229A (pt) |
| CN (1) | CN102105464A (pt) |
| AU (1) | AU2009260503B2 (pt) |
| BR (1) | BRPI0913119A2 (pt) |
| CA (1) | CA2726164A1 (pt) |
| IL (1) | IL209556A0 (pt) |
| WO (1) | WO2009155001A2 (pt) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
| ES2685171T3 (es) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramación de células a un nuevo destino |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| CN102558173B (zh) * | 2010-12-31 | 2015-05-20 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| CN104530042B (zh) * | 2010-12-31 | 2017-11-07 | 广州源生医药科技有限公司 | 抑制wnt信号传导的化合物、组合物及其应用 |
| US9023340B2 (en) * | 2011-07-02 | 2015-05-05 | Chemregen, Inc. | Wnt inhibitors for human stem cell differentiation |
| AU2012308570B2 (en) | 2011-09-14 | 2016-11-10 | Samumed, Llc | Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors |
| WO2013064913A2 (en) * | 2011-10-19 | 2013-05-10 | Hiroyuki Kouji | Method for treating type i and type ii diabetes |
| US9173884B2 (en) * | 2011-11-30 | 2015-11-03 | Trustees Of Boston College | Inhibitors of phosphodiesterase 11 (PDE11) |
| AU2013212175B2 (en) * | 2012-01-28 | 2017-03-02 | Cancer Research Technology Limited | Azaheterocyclic compounds |
| WO2013134079A1 (en) * | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| PH12017500997A1 (en) * | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| US20150157633A1 (en) * | 2012-05-11 | 2015-06-11 | The Board Of Regents Of The University Of Texas System | Wnt protein signalling inhibitors |
| WO2013177349A2 (en) * | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| EP2854780B1 (en) * | 2012-06-05 | 2017-08-30 | University Of Kansas | Inhibitors of respiratory syncytial virus |
| KR101418168B1 (ko) * | 2012-11-21 | 2014-07-09 | 부경대학교 산학협력단 | 신규 테트라하이드로피리디놀 유도체 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물 |
| CN103113353B (zh) * | 2013-03-13 | 2014-09-10 | 中国科学院昆明植物研究所 | 三氮唑类化合物，其药物组合物和其制备方法与应用 |
| CA2910394A1 (en) | 2013-04-26 | 2014-10-30 | Memorial Sloan-Kettering Cancer Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
| WO2014186450A2 (en) * | 2013-05-14 | 2014-11-20 | The Board Of Regents Of The University Of Texas System | Highly potent inhibitors of porcupine |
| EP3028703B1 (en) * | 2013-07-29 | 2019-12-04 | Kyowa Kirin Co., Ltd. | Piperidine derivatives as wnt signaling inhibitor |
| US9512406B2 (en) | 2013-12-20 | 2016-12-06 | The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone | Generating hepatocytes |
| EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
| BR112017007218B1 (pt) | 2014-10-08 | 2023-10-10 | Redx Pharma Plc | Derivados de n-piridil acetamida como inibidores da via de sinalização de wnt, formulações farmacêuticas compreendendo os mesmos e seus usos |
| WO2016179066A1 (en) * | 2015-05-02 | 2016-11-10 | The Board Of Regents Of The University Of Texas System | Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof |
| US10624949B1 (en) | 2015-07-27 | 2020-04-21 | National Technology & Engineering Solutions Of Sandia, Llc | Methods for treating diseases related to the wnt pathway |
| WO2017040579A1 (en) * | 2015-08-31 | 2017-03-09 | The Trustees Of Columbia University In The City Of New York | Methods for cardiac differentiation of human induced pluripotent stem cells |
| CA3004297A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof |
| CN113929662B (zh) * | 2017-12-05 | 2023-01-06 | 中国医学科学院药物研究所 | 琥珀酰亚胺或马来酰亚胺类化合物及其用途 |
| WO2019124603A1 (ko) * | 2017-12-22 | 2019-06-27 | 경상대학교병원 | Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물 |
| EP3749669B1 (en) | 2018-02-06 | 2023-03-08 | Ideaya Biosciences, Inc. | Ahr modulators |
| AU2021226507A1 (en) * | 2020-02-28 | 2022-09-01 | Purdue Research Foundation | Generating aorta-gonad-mesonephros-like hematopoietic cells from human pluripotent stem cells under a defined condition |
| EP4271186A1 (en) * | 2020-12-30 | 2023-11-08 | Arbor Life Holdings, Ltd. | Botanicals as wnt/b-catenin activators, molecular pathway regulators, tissue regenerators and health biomarker regulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002044378A2 (en) | 2000-11-28 | 2002-06-06 | Curis, Inc. | Wnt signalling assay, methods and uses thereof |
| PA8539301A1 (es) | 2001-02-14 | 2002-09-30 | Warner Lambert Co | Inhibidores de la metaloproteinasa de la matriz |
| PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| KR20040048411A (ko) | 2001-09-14 | 2004-06-09 | 메틸진, 인크. | 히스톤 데아세틸라아제의 억제제 |
-
2009
- 2009-05-27 AU AU2009260503A patent/AU2009260503B2/en not_active Ceased
- 2009-05-27 KR KR1020107029281A patent/KR20110014229A/ko not_active Application Discontinuation
- 2009-05-27 WO PCT/US2009/045340 patent/WO2009155001A2/en active Application Filing
- 2009-05-27 CA CA2726164A patent/CA2726164A1/en not_active Abandoned
- 2009-05-27 EP EP09767313.1A patent/EP2303862B1/en not_active Not-in-force
- 2009-05-27 US US12/994,661 patent/US8445491B2/en active Active
- 2009-05-27 BR BRPI0913119-1A patent/BRPI0913119A2/pt not_active IP Right Cessation
- 2009-05-27 CN CN2009801294300A patent/CN102105464A/zh active Pending
- 2009-05-27 JP JP2011511787A patent/JP2011521958A/ja not_active Withdrawn
-
2010
- 2010-11-24 IL IL209556A patent/IL209556A0/en unknown
-
2013
- 2013-05-01 US US13/875,170 patent/US9045416B2/en active Active
-
2015
- 2015-06-02 US US14/728,105 patent/US20150374696A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009155001A3 (en) | 2010-02-25 |
| US20150374696A1 (en) | 2015-12-31 |
| EP2303862A2 (en) | 2011-04-06 |
| JP2011521958A (ja) | 2011-07-28 |
| IL209556A0 (en) | 2011-01-31 |
| US8445491B2 (en) | 2013-05-21 |
| CN102105464A (zh) | 2011-06-22 |
| US20110136813A1 (en) | 2011-06-09 |
| KR20110014229A (ko) | 2011-02-10 |
| US20140038922A1 (en) | 2014-02-06 |
| AU2009260503A1 (en) | 2009-12-23 |
| US9045416B2 (en) | 2015-06-02 |
| AU2009260503B2 (en) | 2014-03-27 |
| WO2009155001A2 (en) | 2009-12-23 |
| EP2303862B1 (en) | 2016-08-24 |
| CA2726164A1 (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0913119A2 (pt) | Inibidores de sinalização de proteína wnt | |
| CY2020023I1 (el) | Αναστολεiς βητα-λακταμασων | |
| CY2019009I2 (el) | Αναστολεις πρωτεϊνικων κινασων | |
| CY2017016I2 (el) | Αναστολεις πρωτεασωματος | |
| BRPI0910668A2 (pt) | inibidores de proteína quinases | |
| BRPI0810365A2 (pt) | Inibidores de mlc-1 de indol 7-substituído | |
| BRPI0807547A2 (pt) | Inibidores de aspartil protease hetercíclicos | |
| CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
| DK2255064T3 (da) | Flerkredsløbs-enkeltledningskontakt | |
| BRPI0906764A2 (pt) | Processos | |
| FI20086175A (fi) | Alus | |
| BRPI0918564A2 (pt) | inibidores | |
| BRPI0814797A2 (pt) | Inibidores dna-pk | |
| BRPI0807911A2 (pt) | Agonistas de alfa2c adrenorreceptor | |
| DK2078895T3 (da) | Belysningssystem | |
| BRPI1013623A2 (pt) | inibidores de ligação de proteína cinase | |
| BRPI0906062A2 (pt) | Inibidores de sinalização de brassinosteróides | |
| BRPI0917563A2 (pt) | porta-objeto | |
| BRPI0918966A2 (pt) | inibidores de protease | |
| IT1393503B1 (it) | Spaccalegna | |
| FI20085200A (fi) | Vesialus | |
| BRPI0919073A2 (pt) | inibidores de protease | |
| NO20080363A (no) | Redningsfartøy | |
| LTC2379528I2 (lt) | Baltymų kinazės slopikliai | |
| AT10397U3 (de) | Leuchte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |